388 related articles for article (PubMed ID: 28395988)
1. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.
Singh I; Morgan C; Curran V; Nutt D; Schlag A; McShane R
Lancet Psychiatry; 2017 May; 4(5):419-426. PubMed ID: 28395988
[TBL] [Abstract][Full Text] [Related]
2. Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective.
López-Díaz Á; Murillo-Izquierdo M; Moreno-Mellado E
Br J Psychiatry; 2019 Aug; 215(2):447-448. PubMed ID: 31030677
[TBL] [Abstract][Full Text] [Related]
3. Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications.
Zhang MW; Harris KM; Ho RC
BMC Med Ethics; 2016 Jan; 17():4. PubMed ID: 26768892
[TBL] [Abstract][Full Text] [Related]
4. Ketamine helps a third of patients with treatment resistant depression, finds small UK study.
Torjesen I
BMJ; 2014 Apr; 348():g2576. PubMed ID: 24699320
[No Abstract] [Full Text] [Related]
5. [Ketamine--a new treatment option for therapy-resistant depression].
Köhler S; Betzler F
Fortschr Neurol Psychiatr; 2015 Feb; 83(2):91-7. PubMed ID: 25723773
[TBL] [Abstract][Full Text] [Related]
6. [Off-label ketamine treatment for treatment-resistant depression: win-win?].
Smith-Apeldoorn SY; Veraart JKE; Schoevers RA
Tijdschr Psychiatr; 2019; 61(8):516-518. PubMed ID: 31512733
[No Abstract] [Full Text] [Related]
7. Esketamine as a treatment for paediatric depression: questions of safety and efficacy.
Zimmermann KS; Richardson R; Baker KD
Lancet Psychiatry; 2020 Oct; 7(10):827-829. PubMed ID: 31952957
[No Abstract] [Full Text] [Related]
8. Is ketamine effective and safe for treatment-resistant depression?
Zorn A; Linn S; Jenkinson M; Neher JO; Safranek S; Kelsberg G
J Fam Pract; 2021 Apr; 70(3):E1-E3. PubMed ID: 34314342
[TBL] [Abstract][Full Text] [Related]
9. Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Gastaldon C; Papola D; Ostuzzi G; Barbui C
Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104
[TBL] [Abstract][Full Text] [Related]
10. Ketamine for Treatment-Resistant Depression: a New Advocate.
Pérez-Esparza R
Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
[TBL] [Abstract][Full Text] [Related]
11. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
Bobo WV; Vande Voort JL; Croarkin PE; Leung JG; Tye SJ; Frye MA
Depress Anxiety; 2016 Aug; 33(8):698-710. PubMed ID: 27062450
[TBL] [Abstract][Full Text] [Related]
12. Ketamine: Future Treatment For Unresponsive Depression?
Frere M; Tepper J
Ir Med J; 2016 Sep; 109(8):453. PubMed ID: 28124853
[TBL] [Abstract][Full Text] [Related]
13. Intravenous ketamine for treatment-resistant major depressive disorder.
Covvey JR; Crawford AN; Lowe DK
Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
[TBL] [Abstract][Full Text] [Related]
14. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
[TBL] [Abstract][Full Text] [Related]
16. Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability.
Kritzer MD; Pae CU; Masand PS
Expert Opin Drug Saf; 2022 Jun; 21(6):725-732. PubMed ID: 35475388
[TBL] [Abstract][Full Text] [Related]
17. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability.
Smith-Apeldoorn SY; Veraart JK; Spijker J; Kamphuis J; Schoevers RA
Lancet Psychiatry; 2022 Nov; 9(11):907-921. PubMed ID: 36244360
[TBL] [Abstract][Full Text] [Related]
18. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development.
Frye MA; Blier P; Tye SJ
J Clin Psychopharmacol; 2015 Jun; 35(3):334-6. PubMed ID: 25928701
[No Abstract] [Full Text] [Related]
19. Ketamine for depression.
Jelen LA; Stone JM
Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
[TBL] [Abstract][Full Text] [Related]
20. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
[No Abstract] [Full Text] [Related]
[Next] [New Search]
